Neville Rodie & Shaw Inc. Sells 2,855 Shares of Johnson & Johnson $JNJ

Key Points

• Neville Rodie & Shaw Inc. has reduced its stake in Johnson & Johnson by 1.7% after selling 2,855 shares, bringing its total ownership to 169,237 shares valued at approximately $25.85 million.
• In recent transactions, insider Jennifer L. Taubert sold over 56,000 shares, resulting in a 24.08% decrease in her ownership.
• Analysts have raised their price targets for Johnson & Johnson, with UBS predicting a target increase to $190.00, reflecting a consensus rating of "Moderate Buy."

Neville Rodie & Shaw Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 169,237 shares of the company's stock after selling 2,855 shares during the period. Johnson & Johnson makes up about 1.9% of Neville Rodie & Shaw Inc.'s holdings, making the stock its 14th largest holding. Neville Rodie & Shaw Inc.'s holdings in Johnson & Johnson were worth $25,851,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Central Pacific Bank Trust Division boosted its holdings in shares of Johnson & Johnson by 0.5% in the second quarter. Central Pacific Bank Trust Division now owns 17,357 shares of the company's stock worth $2,651,000 after acquiring an additional 87 shares during the period. Kera Capital Partners Inc. boosted its holdings in shares of Johnson & Johnson by 33.8% in the second quarter. Kera Capital Partners Inc. now owns 4,116 shares of the company's stock worth $629,000 after acquiring an additional 1,039 shares during the period. Private Client Services LLC boosted its holdings in shares of Johnson & Johnson by 11.2% in the second quarter. Private Client Services LLC now owns 1,816 shares of the company's stock worth $277,000 after acquiring an additional 183 shares during the period. AdviceOne Advisory Services LLC bought a new position in shares of Johnson & Johnson in the first quarter worth $224,000. Finally, AG2R LA Mondiale Gestion D Actifs bought a new position in shares of Johnson & Johnson in the first quarter worth $18,789,000. 69.55% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Down 0.2%

NYSE JNJ opened at $178.10 on Friday. The stock's 50-day simple moving average is $170.81 and its two-hundred day simple moving average is $161.30. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $428.93 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the business posted $2.82 earnings per share. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JNJ. UBS Group raised their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday. Citigroup increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Finally, Morgan Stanley increased their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.